| Literature DB >> 33531865 |
Moamen Refat1, Anas A Sedayo2, Ali Sayqal3, Arwa Alharbi3, Hanadi A Katouah3, Hana M Abumelha4, Seraj Alzahrani5, Fatmah Alkhatib3, Ismail Althagafi3, Nashwa El-Metwaly3,6.
Abstract
The salt of Aurintricarboxylic acid (ATA) was utilized in this study to synthesize new alkaline earth metal ion complexes. The analytical results proposed the isolation of mononuclear (Sr+2&Ba+2) and binuclear complexes (Mg+2&Ca+2). These complexes were analyzed by available analytical and spectral techniques. The tetrahedral geometry was suggested for all complexes (SP3) through bidentate binding mode of ligand with each central atom. UV-Vis spectra reveal the influence of L→M charge transfer and the estimated optical band gap mostly appeared close to that for known semiconductors. XRD, SEM and TEM studies were executed for new complexes and reflects the nano-crystallinity and homogeneous morphology. The structural forms of ATA and its complexes were optimized by DFT/B3LYP under 6-31G and LANL2DZ basis sets. The output files (log, chk &fchk) were visualized on program screen and according to numbering scheme, many physical features were obtained. It is worthy to note that, a virtual simulation for the inhibition affinity towards COVID-19 proteins as proactive study before the actual application, was done for ATA and its complexes. This was done in addition to drugs currently applied in curing (Hydroxychloroquine & Lopinavir), for comparison and recommendation. Drug-likeness parameters were obtained to evaluate the optimal pharmacokinetics to ensure efficacy. Furthermore, simulated inhibition for COVID-19 cell-growth, was conducted by MOE-docking module. The negative allosteric binding mode represents good inhibitory behavior of ATA, Ba(II)-ATA complex and Lopinavir only. All interaction outcomes of Hydroxychloroquine drug reflect unsuitability of this drug in treating COVID-19. On the other hand, there is optimism for ATA and Lopinvir behaviors in controlling COVID-19 proliferation.Entities:
Keywords: ATA and its Alkaline earth metal complexes; Spectroscopy; Synthesis; Virtual study in treating COVID-19
Year: 2021 PMID: 33531865 PMCID: PMC7843113 DOI: 10.1016/j.inoche.2021.108472
Source DB: PubMed Journal: Inorg Chem Commun ISSN: 1387-7003 Impact factor: 2.495
Scheme1. Aurintricarboxylic acid ammonium salt (ATA) ligand.
Analytical and physical properties of ATA and its alkaline earth metal ion complexes.
| Compound Empirical formula | M.P.,°C | % Calculated (Found.) | |||||
|---|---|---|---|---|---|---|---|
| C | H | N | Cl | M | |||
| 1)ATA(C22H23N3O9)(473.43) | 220 | 55.81(55.62) | 4.90(4.66) | 8.88(9.23) | --- | 124.45 | |
| 2)[Mg2Cl4(C22H23N3O9)](663.85) | ˃300 | 39.80(39.30) | 3.49(3.22) | 6.33(6.61) | 21.36(21.33) | 7.32(7.33) | 103.91 |
| 3)[Ca2Cl4(C22H23N3O9)]H2O(713.42) | ˃300 | 37.04(37.31) | 3.53(3.79) | 5.89(6.13) | 19.88(19.71) | 11.24(11.09) | 112.48 |
| 4)[SrCl2(C22H23N3O9)]H2O(649.97) | ˃300 | 40.65(40.23) | 3.88(3.59) | 6.46(6.67) | 10.91(10.78) | 13.48(13.36) | 119.67 |
| 5)[BaCl2(C22H23N3O9)](681.67) | ˃300 | 38.76(38.66) | 3.40(3.16) | 6.16(6.40) | 10.40(10.49) | 20.15(20.20) | 120.13 |
Fig. 1XRD patterns for studied Mg(II), Ca(II), Sr(II) and Ba(II) complexes (A-D).
IR spectra bands (cm−1) of ATA and its alkaline earth metal ion complexes.
| Compound | υs(NH4+) | υ(OH) | δ(OH) | (C = O) | υ(C-O)ac | ρr(H2O) | ρw(H2O) | υ(M−O) |
|---|---|---|---|---|---|---|---|---|
| 1)ATA(C22H23N3O9) | 3430, 3230, 1446 | 3480 | 1380 | 1582, 1662 | 1270 | --- | --- | --- |
| 2)[Mg2Cl4(C22H23N3O9)] | 3327, 3213, 1440 | 3440 | 1365 | 1565, 1624 | 1267 | --- | --- | 520 |
| 3)[Ca2Cl4(C22H23N3O9)]H2O | 3338, 3231, 1434 | 3469 | 1392 | 1565, 1630 | 1250 | 817 | 692 | 562 |
| 4)[SrCl2(C22H23N3O9)]H2O | 3214, 3017, 1446 | 3467 | 1399 | 1570; 1660 | 1256 | 823 | 680 | 526 |
| 5)[BaCl2(C22H23N3O9)] | 3380, 3237, 1434 | 3467 | 1380 | 1580; 1657 | 1149 | --- | --- | 508 |
Fig. 2SEM & TEM for Mg(II), A and Ca(II), B complexes of ATA ligand.
Fig. 3Frontier level maps for the ligand, Mg(II), Ca(II), Sr(II) and Ba(II) complexes(A-E).
Electronic transition bands in ATA and its alkaline earth metal ion complexes.
| Complexes | Color | Intraligand and CT bands (nm); assignment |
|---|---|---|
| 1)ATA(C22H23N3O9) | Red | 559.5 (n → π*), 524.5 (n → σ*), 376.0, 329.4, 294.3(π → π*) |
| 2)[Mg2Cl4(C22H23N3O9)] | Reddish Brown | 546.9, 469.8, 312.5, 265.8 |
| 3)[Ca2Cl4(C22H23N3O9)]H2O | Brown | 551.4, 467.5, 319.2, 267.2 |
| 4)[SrCl2(C22H23N3O9)]H2O | Red | 553.3, 472.7, 319.2, 270.8 |
| 5)[BaCl2(C22H23N3O9)] | Brown | 490.7, 372.8, 286.84 |
Scheme 2The coordination spheres of alkaline earth metal ion complexes from ATA ligand.
Fig. 4Iso-surface with array plots for ATA, Mg(II), Ca(II), Sr(II) and Ba(II) complexes(A-E).
Fig. 5Contact preferences recorded with ATA ligand and suggested drugs towards COVID-19 protein (6lu7 & 6lzg).
Crystal parameters for nano-crystalline complexes by using FWHM method.
| Compounds | Size (Å) | 2θ | Intensity | d-spacing (Å) | ε | δ(Å−2) | FWHM |
|---|---|---|---|---|---|---|---|
| 1)[Ca2Cl4(C22H23N3O9)]H2O | 10.262 | 18.59 | 35,266 | 4.769 | 0.056 | 0.0095 | 0.143 |
| 2)[SrCl2(C22H23N3O9)]H2O | 8.791 | 18.88 | 1857 | 4.696 | 0.064 | 0.0129 | 0.167 |
| 3)[BaCl2(C22H23N3O9)] | 14.90 | 14.54 | 35,652 | 6.087 | 0.049 | 0.0045 | 0.098 |
Drug-likeness parameters for ATA ligand, its alkaline earth metal ion complexes and two drugs.
| Properties | ATA | Mg(II) complex | Ca(II) complex | Sr(II) complex | Ba(II) complex | Hydroxyl-chloroquine | Lopinavir |
|---|---|---|---|---|---|---|---|
| TPSA (Å2) | 127.92 | 167.90 | 159.82 | 168.11 | 145.17 | 48.39 | 120.00 |
| Log | 1.31 | 1.54 | 1.58 | 1.40 | 1.47 | 3.29 | 4.06 |
| GI absorption | High | Low | Low | Low | Low | High | High |
| BBB permeant | No | No | No | No | No | Yes | No |
| Synthetic accessibility(SA) | 3.45 | 4.30 | 4.31 | 4.34 | 4.31 | 2.82 | 5.71 |
| Log | −5.79 cm/s | −5.02 cm/s | −5.21 cm/s | −5.79 cm/s | −6.10 cm/s | −5.81 cm/s | −6.12 cm/s |
Interaction data for new compounds or two reference drugs with COVID-19 cell-proteins.
| Compounds | Proteins | ligand | Receptor | Interaction | Distance(Å) | E (Kcal/mol) | S(energy score) |
|---|---|---|---|---|---|---|---|
| 1)ATA | |||||||
| 6lu7 | O20 | SD MET 165 (A) | H-donor | 3.32 | −0.5 | −6.7357 | |
| 6lzg | O9 | NH1 ARG 219 (A) | H-acceptor | 3.26 | −1.7 | −5.8931 | |
| 2)Mg(II)complex | 6lu7 | O26 | OH TYR 37 (A) | H-acceptor | 3.16 | −1.2 | −1.8707 |
| 6lzg | Mg41 | OD1 ASP 38 (A) | ionic | 2.27 | −11.7 | 0.8686 | |
| 3)Ca(II)complex | 6lu7 | O26 | NZ LYS 61 (A) | ionic | 2.92 | −5.0 | −0.5276 |
| 6lzg | Cl46 | NZ LYS 441 (A) | H-acceptor | 2.87 | −2.7 | 3.1528 | |
| 4)Sr(II)complex | |||||||
| 6lu7 | O31 | SG CYS 145 (A) | H-donor | 3.41 | −1.1 | −2.6354 | |
| 6lzg | C25 | NZ LYS 234 (A) | Ionic | 3.11 | −3.8 | −4.9474 | |
| 5)Ba(II) complex | 6lu7 | O28 | SD MET 165 (A) | H-donor | 3.46 | −1.7 | −6.0648 |
| 6lzg | O30 | NH1 ARG 403 (B) | H-acceptor | 2.93 | −4.4 | −5.5695 | |
| Hydroxychloroquine drug | 6lu7 | --- | --- | --- | --- | --- | −5.2454 |
| 6lzg | O23 | OD1 ASP 367 (A) | H-donor | 2.97 | −3.5 | −6.0729 | |
| Lopinavir drug | 6lu7 | O36 | NZ LYS 5 (A) | H-acceptor | 2.87 | −5.1 | −6.258 |
| 6lzg | N3 | NH1 ARG 403 (B) | H-acceptor pi-H | 3.23 | −2.5 | −7.6147 |